

Egyptian Association of Vascular Biology and Atherosclerosis Consensus on The Usage of SGLT2 Inhibitors in Heart Failure

Ashraf Reda¹, Ahmed Shawky Elserafy², Elsayed Farag³, Tamer Mostafa³, Nabil Farag², Atef Elbahary⁴, Osama Sanad⁵, Mohamed Abdelshafy Tabl⁵, Ahmed Bendary⁵, Ahmed Elkersh¹, Mohamed Ashraf⁶, Ihab Attia², Morad Beshay¹, Hany Ragy⁶, Mohammed Selim⁶, Hazem Khamis⁷

¹Department of Cardiology, Menoufia University, Menoufia, Egypt, ²Department of Cardiology, Ain Shams University, Cairo, Egypt, ³Department of Cardiology, Zagazig University, Zagazig, Egypt, ⁴Cardiology Unit, Port Foad Centre, Port Foad, Egypt, ⁵Department of Cardiology, Banha University, Banha, Egypt, ⁶Department of Cardiology, National heart institute, Cairo, Egypt, ⁷Department of Cardiology, October University, ⁶th of October, Egypt

Corresponding author: ashrafreda5555@gmail.com

Aims: Analysis of SGLT2i data from DAPA-HF and EMPEROR- reduced trials to put a simplified consensus statement on the use of these glucose lowering agents in patients with established heart failure.

Methods and Results: Sixty experts in the field of cardiology revised the literature of the SGLT2i in heart failure, their recommended indications, and their contraindications. Data from DAPA-HF and EMPEROR-reduced trials were tabulated and statistically analysed. SGLT2 inhibitors investigated initially for their glucose lowering capability, have shown a significant benefit in chronic heart failure eit reduced ejection fraction (HFrEF).

Conclusions: We recommend early use of dapagliflozin 10 mg, or empagliflozin 10 mg in patients suffering from symptomatic chronic HFrEF, whether the patient is diabetic or non, to improve heart failure hospitalization, death, symptoms, and decline of renal function.

Keywords: EAVA • Consensus • SGLT2i.

Additional Content: An author video to accompany this abstract is available on <https://academic.oup.com/eurheartjsupp>